Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA

被引:1438
作者
Liu, F [1 ]
Song, YK [1 ]
Liu, D [1 ]
机构
[1] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
关键词
transfection; gene therapy; plasmid DNA; gene expression; hydrodynamics-based transfection;
D O I
10.1038/sj.gt.3300947
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Development of methods that allow an efficient expression of exogenous genes in animals would provide tools for gene function studies, treatment of diseases and for obtaining gene products. Therefore, we have developed a hydrodynamics-based procedure for expressing transgenes in mice by systemic administration of plasmid DNA. Using cDNA of luciferase and beta-galactosidase as a reporter gene, we demonstrated that an efficient gene transfer and expression can be achieved by a rapid injection of a large volume of DMA solution into animals via the fail vein. Among the organs expressing the transgene, the liver showed the highest level of gene expression. AS high as 45 mu g of luciferase protein per gram of liver can be achieved by a single tail vein injection of 5 mu g of plasmid DNA into a mouse. Histochemical analysis using beta-galactosidase gene as a reporter reveals that approximately 40% of hepatocytes express the transgene. The time-response curve shows that the level of transgene expression in the liver reaches the peak level in approximately 8 h after injection and decreases thereafter. The peak level of gene expression can be regained by repeated injection of plasmid DNA. These results suggest that a simple, convenient and efficient method has been developed and which can be used as an effective means for studying gene function, gene regulation and molecular pathophysiology through gene-transfer, as well as for expressing proteins in animals.
引用
收藏
页码:1258 / 1266
页数:9
相关论文
共 29 条
[1]  
BARR D, 1995, GENE THER, V2, P151
[2]  
BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39
[3]   THE RETROVIRAL VECTOR - REPLICATION CYCLE AND SAFETY CONSIDERATIONS FOR RETROVIRUS-MEDIATED GENE-THERAPY [J].
BORISLAWRIE, K ;
TEMIN, HM .
GENE THERAPY FOR NEOPLASTIC DISEASES, 1994, 716 :59-71
[4]  
Budker V, 1996, GENE THER, V3, P593
[5]  
Carter Barrie J., 1992, Current Opinion in Biotechnology, V3, P533, DOI 10.1016/0958-1669(92)90082-T
[6]   Direct cutaneous gene delivery in a human genetic skin disease [J].
Choate, KA ;
Khavari, PA .
HUMAN GENE THERAPY, 1997, 8 (14) :1659-1665
[7]   SAFETY ISSUES RELATED TO RETROVIRAL-MEDIATED GENE-TRANSFER IN HUMANS [J].
CORNETTA, K ;
MORGAN, RA ;
ANDERSON, WF .
HUMAN GENE THERAPY, 1991, 2 (01) :5-14
[8]  
FINK DJ, 1996, ANNU REV NEUROSCI, V19, P245
[9]  
GILBOA E, 1986, BIOTECHNIQUES, V4, P504
[10]   THE SAFETY OF RETROVIRAL VECTORS [J].
GUNTER, KC ;
KHAN, AS ;
NOGUCHI, PD .
HUMAN GENE THERAPY, 1993, 4 (05) :643-645